Abstract:Pancreatic cancer, as one of the most aggressive and lethal malignancies in the world, is lack of effective treatment. Constructing immunotoxin molecules to target the mesothelin (MSLN) receptor is a potential therapeutic strategy for pancreatic cancer and other related malignant tumors, with some molecules being tested in clinical trials. However, currently, there are still some limitations in its applications, such as the difficulty of the preparation of drug molecules, the limited effectiveness of drugs, and the inadequacy of drug safety and immunogenicity. In this study, we constructed a novel type of anti-MSLN immunotoxin, A1-PE24X7, in which a single domain antibody (sdAb) molecule was used as the target ligand and an improved PE24X7 toxin with reduced off-target toxicity and immunogenicity was used as the effector. Unlike conventional immunotoxins, the designed A1-PE24X7 could be easily expressed in the E. coli system in the form of a soluble protein with a good yield (15-20 mg/L), avoiding the complex process of denaturation and refolding of inclusion bodies, and it can be conveniently stored in PBS solution for more than 7 days at 4 degrees C, showing high storage stability. Cell-based experiments showed that A1-PE24X7 entered MSLN-expressing tumor cells in a receptor-mediated manner and killed these cells with an EC50 in the low nanomolar range (0.13 nM against NCI-N87 cells and 0.79 nM against AsPC-1 cells) and it showed ideal selectivity for the MSLN receptor (>100 nM against receptor negative PC3 cells). In animal-based experiments, A1-PE24X7 had tumor enrichment ability in relation to MSLN-positive tumors and showed strong tumor killing and inhibition in mouse models of pancreatic cancer and gastric cancer. Five injections of 3.0 mg/kg A1-PE24X7 significantly reduced the tumor volume of gastric NCI-N87 cancer and also significantly inhibited the growth of pancreatic AsPC-1 cancer. In addition, the maximum tolerable dosage (MSD) of A1-PE24X7 to mice was higher than 15 mg/kg, showing that A1-PE24X7 has a relatively broad therapeutic window. These preclinical results indicate that this strategy has good potential for application to the treatment of pancreatic cancer and other tumors with high MSLN expression.

In Vitro and in Vivo Antitumor Effects of the Recombinant Immunotoxin IL6(T23)-PE38KDEL in Multiple Myeloma.

In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.

Activity of Recombinant Human Interleukin-15 Against Tumor Recurrence and Metastasis in Mice

Data from Treatment of Hepatocellular Carcinoma in Mice with PE38KDEL Type I Mutant-Loaded Poly(lactic-Co-glycolic Acid) Nanoparticles Conjugated with Humanized SM5-1 F(ab′) Fragments

Expression of Recombinant Target Toxin IL-6(23)-PE40KDEL in Pichia Pastoris and Activity of Expressed Product

Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.

Cytotoxic Comparison Between Two Recombinant Immunotoxins of HELβ1-PE38KDEL and HELβ1-PE33 in Selective Therapy for Breast Cancer

iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer

Synergistic Cytotoxic Effect of Immunotoxin HEL PE38KDEL and Cis Platin Against Tumor Cells

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL

The Rational Designed Antagonist Derived from the Complex Structure of Interleukin-6 and Its Receptor Affectively Blocking Interleukin-6 Might Be a Promising Treatment in Multiple Myeloma

Synergistic Antitumor Effects Of 9.2.27-Pe38kdel And Abt-737 In Primary And Metastatic Brain Tumors

Delivery of Interleukin-15 to B16 Melanoma by Electroporation Leads to Tumor Regression and Long-term Survival

The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells

The experimental study on the immunotoxin IL-10_(23-57-)PE40

Pharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted 68Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study

Expression and functional detection of recombinant immunotoxins anti-B7-H4-scFv/PE38KDEL

Preclinical Evaluation of a Novel Anti-Mesothelin Immunotoxin Based on a Single Domain Antibody As the Targeting Ligand

Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy

Preparation and Characterization of PE38KDEL-loaded Anti-Her2 Nanoparticles for Targeted Cancer Therapy

In Vivo and in Vitro Characteristics of Interleukin 6-Transfected B16 Melanoma Cells.